452 related articles for article (PubMed ID: 35933341)
1. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems.
Subramanian DA; Langer R; Traverso G
J Nanobiotechnology; 2022 Aug; 20(1):362. PubMed ID: 35933341
[TBL] [Abstract][Full Text] [Related]
2. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.
Maisel K; Ensign L; Reddy M; Cone R; Hanes J
J Control Release; 2015 Jan; 197():48-57. PubMed ID: 25449804
[TBL] [Abstract][Full Text] [Related]
3. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.
Ensign LM; Cone R; Hanes J
Adv Drug Deliv Rev; 2012 May; 64(6):557-70. PubMed ID: 22212900
[TBL] [Abstract][Full Text] [Related]
4. Mucoadhesive versus mucopenetrating nanoparticles for oral delivery of insulin.
Cheng H; Cui Z; Guo S; Zhang X; Huo Y; Mao S
Acta Biomater; 2021 Nov; 135():506-519. PubMed ID: 34487859
[TBL] [Abstract][Full Text] [Related]
5. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates.
Sheng J; He H; Han L; Qin J; Chen S; Ru G; Li R; Yang P; Wang J; Yang VC
J Control Release; 2016 Jul; 233():181-90. PubMed ID: 27178809
[TBL] [Abstract][Full Text] [Related]
6. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.
Sarparanta MP; Bimbo LM; Mäkilä EM; Salonen JJ; Laaksonen PH; Helariutta AM; Linder MB; Hirvonen JT; Laaksonen TJ; Santos HA; Airaksinen AJ
Biomaterials; 2012 Apr; 33(11):3353-62. PubMed ID: 22285465
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems.
Chater PI; Wilcox MD; Pearson JP
Adv Drug Deliv Rev; 2018 Jan; 124():184-192. PubMed ID: 29247764
[TBL] [Abstract][Full Text] [Related]
8. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers.
Wang Y; Zhao Y; Cui Y; Zhao Q; Zhang Q; Musetti S; Kinghorn KA; Wang S
Acta Biomater; 2018 Jan; 65():405-416. PubMed ID: 29037897
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of Pluronic(®) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats.
Chen D; Xia D; Li X; Zhu Q; Yu H; Zhu C; Gan Y
Int J Pharm; 2013 Jun; 449(1-2):1-9. PubMed ID: 23583840
[TBL] [Abstract][Full Text] [Related]
10. Mucus adhesion- and penetration-enhanced liposomes for paclitaxel oral delivery.
Liu Y; Yang T; Wei S; Zhou C; Lan Y; Cao A; Yang J; Wang W
Int J Pharm; 2018 Feb; 537(1-2):245-256. PubMed ID: 29288808
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.
Date AA; Hanes J; Ensign LM
J Control Release; 2016 Oct; 240():504-526. PubMed ID: 27292178
[TBL] [Abstract][Full Text] [Related]
12. RoboCap: Robotic mucus-clearing capsule for enhanced drug delivery in the gastrointestinal tract.
Srinivasan SS; Alshareef A; Hwang AV; Kang Z; Kuosmanen J; Ishida K; Jenkins J; Liu S; Madani WAM; Lennerz J; Hayward A; Morimoto J; Fitzgerald N; Langer R; Traverso G
Sci Robot; 2022 Sep; 7(70):eabp9066. PubMed ID: 36170378
[TBL] [Abstract][Full Text] [Related]
13. Oral drug delivery with nanoparticles into the gastrointestinal mucosa.
Liu J; Leng P; Liu Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):86-96. PubMed ID: 32749731
[TBL] [Abstract][Full Text] [Related]
14. Engineering strategies to enhance nanoparticle-mediated oral delivery.
Yamanaka YJ; Leong KW
J Biomater Sci Polym Ed; 2008; 19(12):1549-70. PubMed ID: 19017470
[TBL] [Abstract][Full Text] [Related]
15. Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities.
Jiang X; Wang N; Liu C; Zhuo Y; Liang L; Gan Y; Yu M
Drug Discov Today; 2023 Apr; 28(4):103507. PubMed ID: 36690175
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of liposomal behavior in the gastrointestinal tract after oral administration using real-time in vivo imaging.
Tahara K; Nishio M; Takeuchi H
Drug Dev Ind Pharm; 2018 Apr; 44(4):608-614. PubMed ID: 29166794
[TBL] [Abstract][Full Text] [Related]
17. Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption.
Liang Y; Ding R; Wang H; Liu L; He J; Tao Y; Zhao Z; Zhang J; Wang A; Sun K; Li Y; Shi Y
Drug Deliv; 2022 Dec; 29(1):305-315. PubMed ID: 35037529
[TBL] [Abstract][Full Text] [Related]
18. Mucus-penetrating dendritic mesoporous silica nanoparticle loading drug nanocrystal clusters to enhance permeation and intestinal absorption.
Zhou W; Li B; Min R; Zhang Z; Huang G; Chen Y; Shen B; Zheng Q; Yue P
Biomater Sci; 2023 Jan; 11(3):1013-1030. PubMed ID: 36545798
[TBL] [Abstract][Full Text] [Related]
19. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers.
Haddadzadegan S; Dorkoosh F; Bernkop-Schnürch A
Adv Drug Deliv Rev; 2022 Mar; 182():114097. PubMed ID: 34999121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
